New VA program aims to catch silent liver disease in veterans

NCT ID NCT06671886

Recruiting now Knowledge-focused Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new care pathway for non-alcoholic fatty liver disease (NAFLD) in VA primary care. The pathway automatically identifies at-risk patients and educates providers. Researchers will compare this approach to usual care in 32 primary care teams to see if it increases diagnosis and appropriate treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NAFLD Clinical Care Pathway (e-trigger and provider education)
What this could lead to: If successful, this pathway could help more Veterans get diagnosed and treated for NAFLD, potentially preventing serious liver disease.
What could go wrong: This is a small, early-stage trial with only 32 participants, so results may not apply broadly. The intervention is behavioral, not a drug, so impact may be limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASLD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MASLD NAFLD

Contacts and locations

Locations

Michael E. DeBakey VA Medical Center, Houston, TX
RECRUITING

Houston, Texas, 77030-4211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.